Above all, we make a difference.

Screening & Early Detection References

  

  1. Howlader N, Noone AM, Krapcho M, et al. (editors). Cancer Statistics Review, 1975-2017. Table 4.6: Cancer of the breast (invasive). Age-adjusted U.S. death rates by year, race and sex. National Cancer Institute. Bethesda, MD. Accessed on May 8, 2020. https://seer.cancer.gov/csr/1975_2017/, 2020.
  2. Siu AL on behalf of the U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 164(4):279-96, 2016. 
  3. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Breast cancer screening and diagnosis, Version 1.2019. http://www.nccn.org, 2020.
  4. American Cancer Society. American Cancer Society recommendations for the early detection of breast cancer. https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html, 2020.
  5. Yaffe MJ, Mainprize JG. Risk of radiation-induced breast cancer from mammographic screening. Radiology. 258(1):98-105, 2011.
  6. de Gelder R, Draisma G, Heijnsdijk EA, de Koning HJ. Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deaths. Br J Cancer. 104(7):1214-20, 2011.
  7. Miglioretti DL, Lange J, van den Broek JJ, et al. Radiation-induced breast cancer incidence and mortality from digital mammography screening: a modeling study. Ann Intern Med. 164(4):205-14, 2016.
  8. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 6:CD001877, 2013.
  9. Skaane P, Bandos AI, Gullien R, et al. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology. 267(1):47-56, 2013.
  10. Melnikow J, Fenton JJ, Whitlock EP, et al. Supplemental screening for breast cancer in women with dense breasts: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 164(4):268-78, 2016.
  11. Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 311(24):2499-2507, 2014.
  12. Bernardi D, Macaskill P, Pellegrini M, et al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 17(8):1105-13, 2016.
  13. Pattacini P, Nitrosi A, Giorgi Rossi P, et al. For the RETomo Working Group. Digital mammography versus digital mammography plus tomosynthesis for breast cancer screening: The Reggio Emilia Tomosynthesis randomized trial. Radiology. 288(2):375-385, 2018.
  14. Marinovich ML, Hunter KE, Macaskill P, Houssami N. Breast cancer screening using tomosynthesis or mammography: a meta-analysis of cancer detection and recall. J Natl Cancer Inst. 110(9):942-949, 2018.
  15. Conant EF, Zuckerman SP, McDonald ES, et al. Five consecutive years of screening with digital breast tomosynthesis: outcomes by screening year and round. Radiology. 295(2):285-293, 2020.
  16. U.S. Centers for Medicare & Medicaid Services. Preventive care benefits for women. https://www.healthcare.gov/preventive-care-women/, 2020.
  17. Grabler P, Sighoko D, Wang L, Allgood K, Ansell D. Recall and cancer detection rates for screening mammography: finding the sweet spot. AJR Am J Roentgenol. 208(1):208-213, 2017.
  18. Breast Cancer Surveillance Consortium (BCSC). Abnormal interpretations for 1,682,504 screening mammography examinations from 2007-2013. https://www.bcsc-research.org/statistics/screening-performance-benchmarks/abnormal-interpretations, 2017.
  19. Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 155(8):481-92, 2011.
  20. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 380(9855):1778-86, 2012.
  21. Nelson HD, Pappas M, Cantor A, Griffin J, Daeges M, Humphrey L. Harms of breast cancer screening: systematic review to update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 164(4):256-67, 2016.
  22. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 356(3):227-36, 2007.
  23. Yaghjyan L, Colditz GA, Collins LC, et al. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst. 103(15):1179-89, 2011.
  24. Conant EF, Barlow WE, Herschorn SD, et al. Association of digital breast tomosynthesis vs digital mammography with cancer detection and recall rates by age and breast density. JAMA Oncol. 5(5):635–642, 2019.
  25. Canadian Cancer Society. Breast calcifications. https://www.cancer.ca/en/cancer-information/cancer-type/breast/breast-cancer/breast-calcifications/?region=on, 2020.
  26. D’Orsi CJ, Sickles EA, Mendelson EB, et al. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. Reston, VA. American College of Radiology, 2013.
  27. American Cancer Society. Understanding your mammogram report. https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/mammograms/understanding-your-mammogram-report.html, 2019.
  28. Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 164(4):244-55, 2016.
  29. Wilt TJ, Harris RP, Qaseem A for the High Value Care Task Force of the American College of Physicians. Screening for cancer: advice for high-value care from the American College of Physicians. Ann Intern Med. 162(10):718-25, 2015.
  30. American Geriatrics Society. Choosing wisely. http://www.choosingwisely.org/clinician-lists/american-geriatrics-society-breast-colorectal-prostate-cancer-screening-in-older-adults/, 2015.
  31. Breast Cancer Surveillance Consortium (BCSC). Sensitivity, specificity, and false negative rate for 1,682,504 screening mammography examinations from 2007-2013. https://www.bcsc-research.org/statistics/screening-performance-benchmarks/screening-sens-spec-false-negative, 2017.
  32. Kerlikowske K, Zhu W, Hubbard RA, et al. for the Breast Cancer Surveillance Consortium. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med. 173(9):807-16, 2013.
  33. Tosteson AN, Fryback DG, Hammond CS, et al. Consequences of false-positive screening mammograms. JAMA Intern Med. 174(6):954-61, 2014.
  34. Bolejko A, Hagell P, Wann-Hansson C, Zackrisson S. Prevalence, long-term development, and predictors of psychosocial consequences of false-positive mammography among women attending population-based screening. Cancer Epidemiol Biomarkers Prev. 24(9):1388-97, 2015.
  35. Rossouw JE, Anderson GL, Prentice RL, et al. for the Women’s Health Initiative (WHI) Investigators Writing Group. Risk and benefits of estrogen plus progestin in health postmenopausal women: Principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA. 288(3):321-33, 2002.
  36. U.S. Food and Drug Administration. Menopause. https://www.fda.gov/consumers/womens-health-topics/menopause, 2019.
  37. Chlebowski RT, Hendrix SL, Langer RD, et al. for the Women’s Health Initiative Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial. JAMA. 289(24):3243-53, 2003.
  38. Chlebowski RT, Anderson G, Manson JE, et al. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol. 28(16):2690-7, 2010.
  39. McTiernan A, Martin CF, Peck JD, et al. for the Women’s Health Initiative Mammogram Density Study Investigators. Estrogen-plus-progestin use and mammographic density in postmenopausal women: women’s health initiative randomized trial. J Natl Cancer Inst. 97(18):1366-76, 2005.
  40. Stefanick ML, Anderson GL, Margolis KL, et al. for the Women’s Health Initiative Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 295(14):1647-57, 2006.
  41. McTiernan A, Chlebowski RT, Martin C, et al. for the Women’s Health Initiative Investigators. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women’s health initiative randomized trial. J Clin Oncol. 27(36):6135-43, 2009.
  42. Rawashdeh MA, Lee WB, Bourne RM, et al. Markers of good performance in mammography depend on number of annual readings. Radiology. 269(1):61-7, 2013.
  43. Théberge I, Chang SL, Vandal N, et al. Radiologist interpretive volume and breast cancer screening accuracy in a Canadian organized screening program. J Natl Cancer Inst. 106(3):djt461, 2014.
  44. Giess CS, Wang A, Ip IK, Lacson R, Pourjabbar S, Khorasani R. Patient, radiologist, and examination characteristics affecting screening mammography recall rates in a large academic practice. J Am Coll Radiol. 16(4 Pt A):411-418, 2019.
  45. Lee CS, Bhargavan-Chatfield M, Burnside ES, Nagy P, Sickles EA. The National Mammography Database: preliminary data. AJR Am J Roentgenol. 206(4):883-90, 2016.
  46. Stout NK, Lee SJ, Schechter CB, et al. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst. 106(6):dju092, 2014.
  47. Slanetz PJ, Moy L, Baron P, et al. for the Expert Panel on Breast Imaging. ACR Appropriateness Criteria® monitoring response to neoadjuvant systemic therapy for breast cancer. J Am Coll Radiol. 14(11S):S462-S475, 2017.
  48. Howlader N, Noone AM, Krapcho M, et al. (editors). SEER*Explorer. Breast cancer: SEER incidence rates by age at diagnosis, 2013-2017, by sex, all races. National Cancer Institute. Bethesda, MD. Accessed on June 6, 2020. https://seer.cancer.gov/explorer/, 2020.
  49. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 348:g366, 2014.
  50. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl PH. Breast cancer screening in Denmark: a cohort study of tumor size and overdiagnosis. Ann Intern Med. 166(5):313-323, 2017.
  51. Autier P, Boniol M, Koechlin A, Pizot C, Boniol M. Effectiveness of and overdiagnosis from mammography screening in the Netherlands: population based study. BMJ. 359:j5224, 2017.
  52. Katalinic A, Eisemann N, Kraywinkel K, Noftz MR, Hübner J. Breast cancer incidence and mortality before and after implementation of the German Mammography Screening Program. Int J Cancer. 147(3):709-718, 2020.
  53. Myers ER, Moorman P, Gierisch JM, et al. Benefits and harms of breast cancer screening: a systematic review. JAMA. 314(15):1615-34, 2015.
  54. Van Zee KJ, White J, Morrow M, Harris JR. Chapter 23: Ductal carcinoma in situ and microinvasive carcinoma, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  55. Visser LL, Groen EJ, van Leeuwen FE, Lips EH, Schmidt MK, Wesseling J. Predictors of an invasive breast cancer recurrence after DCIS: a systematic review and meta-analyses. Cancer Epidemiol Biomarkers Prev. 28(5):835-845, 2019.
  56. Centers for Disease Control and Prevention. What are the symptoms of breast cancer? http://www.cdc.gov/cancer/breast/basic_info/symptoms.htm, 2018.
  57. American Cancer Society. Breast cancer signs and symptoms. https://www.cancer.org/cancer/breast-cancer/about/breast-cancer-signs-and-symptoms.html, 2019.
  58. Kosters JP, Gotzsche PC. Regular self-examination or clinical examination for early detection of breast cancer (review). Cochrane Database Syst Rev. Issue 3: CD003373, 2008.
  59. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Genetic/familial high-risk assessment: breast, ovarian, and pancreatic. Version 1.2020. http://www.nccn.org, 2020.
  60. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast cancer, Version 4.2020. http://www.nccn.org, 2020.
  61. Saslow D, Boetes C, Burke W, et al. for the American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 57(2):75-89, 2007.
  62. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med. 148(9):671-9, 2008.
  63. Lowry KP, Lee JM, Kong CY, et al. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis. Cancer. 118(8):2021-30, 2012.
  64. Chiarelli AM, Prummel MV, Muradali D, et al. Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the Ontario High Risk Breast Screening Program. J Clin Oncol. 32(21):2224-30, 2014.
  65. American Cancer Society. Breast Cancer Facts and Figures 2019-2020. Atlanta, GA: American Cancer Society, 2019.
  66. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 99(23):1811-4, 2007.
  67. National Cancer Institute. Genetics of breast and gynecologic cancers (PDQ®) – health professional version. https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq, 2020.
  68. Jain S and Gradishar WJ. Chapter 61: Male Breast Cancer. In Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott, Williams and Wilkins, 2014.
  69. American Cancer Society. Signs and symptoms of breast cancer in men. https://www.cancer.org/cancer/breast-cancer-in-men/detection-diagnosis-staging/signs-symptoms.html, 2018.
  70. Lehman CD, Gatsonis C, Kuhl CK, et al. for the ACRIN Trial 6667 Investigators Group. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 356(13):1295-303, 2007.
  71. Shah C, Ahlawat S, Khan A, et al. The role of MRI in the follow-up of women undergoing breast-conserving therapy. Am J Clin Oncol. 39(3):314-9, 2016.
  72. Buist DSM, Abraham L, Lee CI, et al. for the Breast Cancer Surveillance Consortium. Breast biopsy intensity and findings following breast cancer screening in women with and without a personal history of breast cancer. JAMA Intern Med. 178(4):458-468, 2018.
  73. Mallio CA, Rovira A, Parizel PM, Quattrocchi CC. Exposure to gadolinium and neurotoxicity: current status of preclinical and clinical studies. Neuroradiology. 62(8):925-934, 2020.
  74. Sippo DA, Burk KS, Mercaldo SF, et al. Performance of screening breast MRI across women with different elevated breast cancer risk indications. Radiology. 292(1):51-59, 2019.
  75. Cho N, Han W, Han BK, et al. Breast cancer screening with mammography plus ultrasonography or magnetic resonance imaging in women 50 years or younger at diagnosis and treated with breast conservation therapy. JAMA Oncol. 3(11):1495-1502, 2017.
  76. Berg WA, Zhang Z, Lehrer D, et al. for the ACRIN 6666 Investigators. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 307(13):1394-404, 2012.
  77. O’Flynn EA, Ledger AE, deSouza NM. Alternative screening for dense breasts: MRI. AJR Am J Roentgenol. 204(2):W141-9, 2015.
  78. Bakker MF, de Lange SV, Pijnappel RM, et al. for the DENSE Trial Study Group. Supplemental MRI screening for women with extremely dense breast tissue. N Engl J Med. 381(22):2091-2102, 2019.
  79. Gartlehner G, Thaler K, Chapman A, et al. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. Cochrane Database Syst Rev. 4:CD009632, 2013.
  80. Scheel JR, Lee JM, Sprague BL, Lee CI, Lehman CD. Screening ultrasound as an adjunct to mammography in women with mammographically dense breasts. Am J Obstet Gynecol. 212(1):9-17. 2015.
  81. Giger ML, Inciardi MF, Edwards A, et al. Automated breast ultrasound in breast cancer screening of women with dense breasts: reader study of mammography-negative and mammography-positive cancers. AJR Am J Roentgenol. 206(6):1341-50, 2016.
  82. Tagliafico AS, Calabrese M, Mariscotti G, et al. Adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts: interim report of a prospective comparative trial. J Clin Oncol. 34(16):1882-8, 2016.
  83. Rebolj M, Assi V, Brentnall A, Parmar D, Duffy SW. Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis. Br J Cancer. 118(12):1559-1570, 2018.
  84. Yuan WH, Hsu HC, Chen YY, Wu CH. Supplemental breast cancer-screening ultrasonography in women with dense breasts: a systematic review and meta-analysis. Br J Cancer. 2020 Jun 12 [Online ahead of print].
  85. Riedl CC, Luft N, Bernhart C, et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol. 33(10):1128-35, 2015.
  86. Shermis RB, Wilson KD, Doyle MT, et al. Supplemental breast cancer screening with molecular breast imaging for women with dense breast tissue. AJR Am J Roentgenol. 207(2):450-7, 2016.
  87. Mainiero MB, Lourenco A, Mahoney MC, et al. ACR Appropriateness Criteria breast cancer screening. J Am Coll Radiol. 13(11S):R45-R49, 2016.
  88. Hendrick RE. Radiation doses and cancer risks from breast imaging studies. Radiology. 257(1):246-53, 2010.
  89. Hruska CB. Molecular breast imaging for screening in dense breasts: state of the art and future directions. AJR Am J Roentgenol. 208(2):275-283, 2017.
  90. Rhodes DJ, Hruska CB, Conners AL, et al. Journal Club: Molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts. AJR Am J Roentgenol. 204(2):241-51, 2015.
  91. Sogani J, Morris E, Kaplan J, et al. Comparison of background parenchymal enhancement at contrast-enhanced spectral mammography and breast MR imaging. Radiology. 282:63–73, 2017.
  92. Covington MF, Pizzitola VJ, Lorans R, et al. The future of contrast-enhanced mammography. AJR Am J Roentgenol. 210(2):292-300, 2018.
  93. Kuhl CK, Schrading S, Strobel K, Schild HH, Hilgers RD2 Bieling HB. Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI. J Clin Oncol. 32(22):2304-10, 2014.
  94. Harvey SC, Di Carlo PA, et al. An abbreviated protocol for high-risk screening breast MRI saves time and resources. J Am Coll Radiol. 2016 Nov;13(11S):R74-R80.
  95. Choi BH, Choi N, Kim MY, Yang JH, Yoo YB, Jung HK. Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery. Breast Cancer Res Treat. 167(2):495-502, 2018.
  96. Comstock CE, Gatsonis C, Newstead GM, et al. Comparison of abbreviated breast MRI vs digital breast tomosynthesis for breast cancer detection among women with dense breasts undergoing screening. JAMA. 323(8):746-756, 2020.
  97. Duric N, Boyd N, Littrup P, et al. Breast density measurements with ultrasound tomography: a comparison with film and digital mammography. Med Phys. 40(1):013501, 2013.
  98. Lee CI and Elmore JC. Chapter 11. Breast Cancer Screening, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  99. U.S. Food and Drug Administration (FDA). Breast cancer screening: thermogram no substitute for mammogram. https://www.fda.gov/forconsumers/consumerupdates/ucm257499.htm, 2017.
  100. U.S. Food and Drug Administration (FDA). FDA warns thermography should not be used in place of mammography to detect, diagnose, or screen for breast cancer: FDA safety communication. https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm631885.htm, 2019.
  101. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures, 2019-2020. Atlanta, GA: American Cancer Society, 2019.
  102. Plescia M, White MC. The National Prevention Strategy and breast cancer screening: scientific evidence for public health action. Am J Public Health. 103(9):1545-8, 2013.
  103. Fayanju OM, Kraenzle S, Drake BF, Oka M, Goodman MS. Perceived barriers to mammography among underserved women in a Breast Health Center Outreach Program. Am J Surg. 208(3):425-34, 2014.
  104. Ramachandran A, Snyder FR, Katz ML, et al. for the Patient Navigation Research Program Investigators. Barriers to health care contribute to delays in follow-up among women with abnormal cancer screening: data from the Patient Navigation Research Program. Cancer. 121(22):4016-24, 2015.
  105. Shoemaker ML, White MC. Breast and cervical cancer screening among Hispanic subgroups in the USA: estimates from the National Health Interview Survey 2008, 2010, and 2013. Cancer Causes Control. 27(3):453-7, 2016.
  106. Shoemaker ML, White MC. Breast and cervical cancer screening among Asian subgroups in the USA: estimates from the National Health Interview Survey, 2008, 2010, and 2013. Cancer Causes Control. 27(6):825-9, 2016.
  107. White A, Thompson TD, White MC, et al. Cancer screening test use – United States, 2015. MMWR Morb Mortal Wkly Rep. 66(8):201-206, 2017.
  108. Henderson LM, O’Meara ES, Haas JS, et al. The role of social determinants of health in self-reported access to health care among women undergoing screening mammography. J Womens Health (Larchmt). 2020 May 5 [Online ahead of print].
  109. Howlader N, Noone AM, Krapcho M, et al. (editors). SEER Cancer Statistics Review, 1975-2017. Table 4.18. Cancer of the female breast (invasive): Age-adjusted rates and trends by race/ethnicity, 2013-2017. National Cancer Institute. Bethesda, MD. Accessed on June 13, 2020. http://seer.cancer.gov/csr/1975_2017/, 2020.
  110. American Cancer Society. Cancer Facts and Figures for African Americans 2019-2021. Atlanta, GA: American Cancer Society, 2019.
  111. Howlader N, Noone AM, Krapcho M, et al. (editors). Cancer Statistics Review, 1975-2017. Table 4.8: Age-adjusted SEER incidence rates by year, race and age. National Cancer Institute. Bethesda, MD. Accessed on April 27, 2020. https://seer.cancer.gov/csr/1975_2017/, 2020.
  112. Howlader N, Noone AM, Krapcho M, et al. (editors). Cancer Statistics Review, 1975-2017. Table 4.9: Age-adjusted SEER death rates by year, race and age. National Cancer Institute. Bethesda, MD. Accessed on April 27, 2020. https://seer.cancer.gov/csr/1975_2017/, 2020.
  113. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 56(3):168-83, 2006.
  114. Battaglia TA, Santana MC, Bak S, et al. Predictors of timely follow-up after abnormal cancer screening among women seeking care at urban community health centers. Cancer. 116(4):913-21, 2010.
  115. Warner ET, Tamimi RM, Hughes ME, et al. Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Res Treat. 136(3):813-21, 2012.
  116. DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 69(3):211-233, 2019.
  117. Curtis E, Quale C, Haggstrom D, Smith-Bindman R. Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer. 112(1):171-80, 2008.
  118. George P, Chandwani S, Gabel M, et al. Diagnosis and surgical delays in African American and white women with early-stage breast cancer. J Womens Health (Larchmt). 24(3):209-17, 2015.
  119. Chen L, Li CI. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. Cancer Epidemiol Biomarkers Prev. 24(11):1666-72, 2015.
  120. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 313(2):165-73, 2015.
  121. Warner ET, Tamimi RM, Boggs DA, et al. Estrogen receptor positive tumors: do reproductive factors explain differences in incidence between black and white women? Cancer Causes Control. 24(4):731-9, 2013.
  122. Warner ET, Tamimi RM, Hughes ME, et al. Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol. 33(20):2254-61, 2015.
  123. Chen L, Li CI, Tang MT, et al. Reproductive factors and risk of luminal, HER2-overexpressing, and triple-negative breast cancer among multiethnic women. Cancer Epidemiol Biomarkers Prev. 25(9):1297-304, 2016.
  124. Jemal A, Robbins AS, Lin CC, et al. Factors that contributed to black-white disparities in survival among nonelderly women with breast cancer between 2004 and 2013. J Clin Oncol. 36(1):14-24, 2018.
  125. Walsh SM, Zabor EC, Stempel M, Morrow M, Gemignani ML. Does race predict survival for women with invasive breast cancer? Cancer. 125(18):3139-3146, 2019.
  126. American Cancer Society. Cancer Facts and Figures for Hispanics/Latinos, 2018-2020. Atlanta, GA: American Cancer Society, 2018.
  127. American Cancer Society. Cancer Facts and Figures 2020. Atlanta, GA: American Cancer Society, 2020.
  128. Towne SD Jr, Smith ML, Ory MG. Geographic variations in access and utilization of cancer screening services: examining disparities among American Indian and Alaska Native Elders. Int J Health Geogr. 13:18, 2014.
  129. Melkonian SC, Jim MA, Haverkamp D, et al. Disparities in cancer incidence and trends among American Indians and Alaska Natives in the United States, 2010-2015. Cancer Epidemiol Biomarkers Prev. 28(10):1604-1611, 2019.
  130. Gopalani SV, Janitz AE, Martinez SA, Gutman P, Khan S, Campbell JE. Trends in cancer incidence among American Indians and Alaska Natives and non-Hispanic Whites in the United States, 1999-2015. Epidemiology. 31(2):205-213, 2020.
  131. Nguyen KH, Pasick RJ, Stewart SL, Kerlikowske K, Karliner LS. Disparities in abnormal mammogram follow-up time for Asian women compared with non-Hispanic white women and between Asian ethnic groups. Cancer. 123(18):3468-3475, 2017.
  132. Austin SB, Pazaris MJ, Nichols LP, Bowen D, Wei EK, Spiegelman D. An examination of sexual orientation group patterns in mammographic and colorectal screening in a cohort of U.S. women. Cancer Causes Control. 24(3):539-47, 2013.
  133. Hart SL, Bowen DJ. Sexual orientation and intentions to obtain breast cancer screening. J Womens Health (Larchmt). 18(2):177-85, 2009.
  134. Williams AD, Bleicher RJ, Ciocca RM. Breast cancer risk, screening, and prevalence among sexual minority women: an analysis of the National Health Interview Survey. LGBT Health. 7(2):109-118, 2020.
  135. Horner-Johnson W, Dobbertin K, Andresen EM, Iezzoni LI. Breast and cervical cancer screening disparities associated with disability severity. Womens Health Issues. 24(1):e147-53, 2014.
  136. Centers for Disease Control and Prevention. Women with disabilities and breast cancer screening. http://www.cdc.gov/ncbddd/disabilityandhealth/breast-cancer-screening.html, 2019.
  137. Yankaskas BC, Dickens P, Bowling JM, et al. Barriers to adherence to screening mammography among women with disabilities. Am J Public Health. 100(5):947-53, 2010.
  138. Courtney-Long E, Armour B, Frammartino B, Miller J. Factors associated with self-reported mammography use for women with and women without a disability. J Womens Health (Larchmt). 20(9):1279-86, 2011.
  139. Ramjan L, Cotton A, Algoso M, Peters K. Barriers to breast and cervical cancer screening for women with physical disability: a review. Women Health. 56(2):141-56, 2016.
  140. Centers for Disease Control and Prevention. Disability and health information for women with disabilities. http://www.cdc.gov/ncbddd/disabilityandhealth/women.html, 2019.
  141. Alexandraki I, Mooradian AD. Barriers related to mammography use for breast cancer screening among minority women. J Natl Med Assoc. 102(3):206-18, 2010.
  142. Khushalani JS, Ekwueme DU, Richards TB, et al. Utilization and cost of mammography screening among commercially insured women 50 to 64 years of age in the United States, 2012-2016. J Womens Health (Larchmt). 29(3):327-337, 2020.
  143. Cooper GS, Kou TD, Dor A, Koroukian SM, Schluchter MD. Cancer preventive services, socioeconomic status, and the Affordable Care Act. Cancer. 123(9):1585-1589, 2017. 

Updated 08/10/20

010673.gif

Screening and Early Detection Home

  

 

TOOLS & RESOURCES

Video

Related Video